Treating Renal Cell Carcinoma With Tyrosine Kinase Inhibition

Tailoring TKI Dosing Strategies to Real-World Patients With RCC

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Oncologists Discuss Choice of Frontline IO/TKI for Metastatic RCC

During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.

Unknowns Remain in Frontline RCC Treatment and Adjuvant Approaches

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

Current Physician Treatment Preferences for Frontline Metastatic ccRCC

Explore the evolving treatment strategies for metastatic clear cell renal cell carcinoma, highlighting innovative combination therapies and their efficacy.

Frontline Metastatic RCC Therapy Improved With Long-Term Data

Bradley A. McGregor, MD, discusses the advancements in treating metastatic renal cell carcinoma.

RCC Treatment Selection Should Incorporate Patient Discussion and Goals

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

IO/IO Vs IO/TKI Usage in Frontline RCC Varies Across Clinical Practice

Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.

Ensuring Response and Tolerable Dose Are Crucial in RCC

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.

Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.

Comparing VEGF TKI/IO Vs IO/IO Combination Efficacy in Metastatic RCC

During a live event, Guru P. Sonpavde, MD discussed first-line renal cell carcinoma regimens with varying efficacy and toxicity profiles.

Participants Explain Rationale for Different IO/TKI Options for ccRCC

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.

Biomarkers Have Potential to Shape Treatment of RCC

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell carcinoma.

What's Next for Frontline Metastatic RCC Therapy

Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma therapy.

Primary Progressive Disease Rate Supports IO/TKI Use in Frontline mRCC

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients with metastatic renal cell carcinoma.

Considering How Favorable Risk Affects Treatment in ccRCC

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.

Participants Discuss Differences in Treatment in First-Line mRCC

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate and poor-risk renal cell carcinoma.

Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.

GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.

Frontline Cabo/Nivo in RCC Supported by Risk Status, Metastasis Analyses

During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated data from the CheckMate 9ER trial of patients with advanced renal cell carcinoma in the second article of a 2-part series.

Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC

During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.

Comparing Choices for IO/TKI Combinations in Advanced RCC

During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.

Deciding Factors for Front-Line Therapy in Metastatic RCC

During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.

Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

Risk Stratification Influences Choice of Frontline IO/TKI Regimen in mRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.

Management of Serious Toxicities with Cabozantinib/Nivolumab in mRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.

Updated Data Shows Durable Efficacy of Cabozantinib/Nivolumab in mRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.

Treatment Selection and Dosing Strategies Based on Trial Data in RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.

Risk Stratification Influences Approach in Frontline Advanced RCC Care

In the first article of a 2-part series, Benjamin Garmezy, MD, discusses risk stratification and combination options in the metastatic clear cell renal cell carcinoma setting.

Physicians Discuss Counseling on Immunotherapy Discontinuation in RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Real-World Factors Influence Choice of IO/TKI Regimen for mRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

Selecting IO/TKI Therapy for mRCC Based on Patient Profile

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.

Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.

Physicians Discuss Potential of Frontline Triplet Regimens for RCC

During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.

Reviewing Updated Survival and Subgroup Data of CheckMate9ER for RCC

During a Targeted Oncology case-based roundtable event, Eric Jonasch, MD, discussed the efficacy of the CheckMate 9ER regimen for patients with renal cell carcinoma.

Comparing Physician Experience With Trial Data for Frontline RCC Regimens

During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.

Choosing Frontline RCC Therapy After Detecting Metastases in Patient Under Observation

During a Targeted Oncology case-based roundtable event, Sumanta K. Pal, MD, discussed the choice of frontline therapy for a favorable-risk patient with advanced clear cell renal cell carcinoma.

POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.

Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies

During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.